title: Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use?
abstract: BACKGROUND
  Medication for the relief of heartburn should have the rapid onset of action required for on-demand use. We studied the inhibition of gastric acid secretion by lafutidine and rabeprazole, given in single doses to fasting and postprandial subjects.
  
  
  METHODS
  A total of 22 healthy male, Helicobacter pylori-negative volunteers participated in this randomized, two-way crossover study. They were randomly assigned to receive a single oral dose of 10 mg lafutidine or 20 mg rabeprazole after fasting overnight (12 subjects, fasting study) or after eating a test meal (noodles, 364 kcal; protein, 10.1 g; fat, 16 g; carbohydrates, 44.9 g; NaCl, 1.1 g; 10 subjects, postprandial study). Intragastric pH was monitored continuously for 6 h after treatment. The other drug was given after a washout period of at least 7 days, and intragastric pH was similarly monitored.
  
  
  RESULTS
  In the fasting study, lafutidine sustained pH at >3 and >4 during the second, third, fourth, fifth, and sixth hours of the study for significantly longer than rabeprazole. During the first 6 h after treatment, lafutidine sustained pH at more than 2, 3, 3.5, 4, 5, 6, and 7 longer than rabeprazole. In the postprandial study, lafutidine sustained pH >3 and >4 for longer periods than rabeprazole during the third, fourth, fifth, and sixth hours of the study. During the first 6 h after treatment, lafutidine sustained pH at more than 2, 3, 3.5, 4, 5, 6, and 7 longer than rabeprazole.
  
  
  CONCLUSIONS
  Lafutidine 10 mg produces a prompter rise in intragastric pH than rabeprazole 20 mg in fasting and postprandial Helicobacter pylori-negative male subjects.
authors.affiliation: Gastroenterology Division, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Inamori
authors.forename: Jun-Ichi
authors.initials: J
authors.lastname: Togawa
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Iwasaki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Ozawa
authors.forename: Taisuke
authors.initials: T
authors.lastname: Kikuchi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Muramatsu
authors.forename: Gaku
authors.initials: G
authors.lastname: Chiguchi
authors.forename: Shuhei
authors.initials: S
authors.lastname: Matsumoto
authors.forename: Harunobu
authors.initials: H
authors.lastname: Kawamura
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Abe
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kirikoshi
authors.forename: Noritoshi
authors.initials: N
authors.lastname: Kobayashi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Shimamura
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kubota
authors.forename: Takashi
authors.initials: T
authors.lastname: Sakaguchi
authors.forename: Satoru
authors.initials: S
authors.lastname: Saito
authors.forename: Norio
authors.initials: N
authors.lastname: Ueno
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakajima
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000081:Acetamides / Q000008:administration & dosage*; D000284:Administration, Oral; D000328:Adult; D001562:Benzimidazoles / Q000008:administration & dosage*; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D005744:Gastric Acid / Q000378:metabolism; D005745:Gastric Acidity Determination; D006356:Heartburn / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008991:Monitoring, Physiologic; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010880:Piperidines / Q000008:administration & dosage*; D019518:Postprandial Period / Q000187:drug effects*; D011725:Pyridines / Q000008:administration & dosage*; D064750:Rabeprazole; D012016:Reference Values; D018570:Risk Assessment; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000081:Acetamides; D001562:Benzimidazoles; D010880:Piperidines; D011725:Pyridines; D064750:Rabeprazole; C076948:lafutidine; D009853:Omeprazole